Trial Profile

A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of a Single Intravenous Injection IBI311 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI-311 (Primary)
Indications Eye disorders; Graves ophthalmopathy
Focus Adverse reactions
Sponsors Innovent Biologics

Most Recent Events

09 Oct 2023 Status changed from recruiting to completed.
17 Aug 2022 According to Innovent Biologics media release, the first healthy volunteer has been successfully dosed in this Phase 1 study
17 Aug 2022 Status changed from not yet recruiting to recruiting as per Innovent Biologics media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com